Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

728

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Type2 DiabetesHigh Blood Sugar
Interventions
DRUG

Dapagliflozin

Oral Dose 5 or 10 mg

Trial Locations (38)

Unknown

Research Site, Nagoya

Research Site, Owariasahi

Research Site, Toyohashi

Research Site, Hirosaki

Research Site, Niihama

Research Site, Fukuoka

Research Site, Itoshima

Research Site, Yukuhashi

Research Site, Annaka

Research Site, Ōta

Research Site, Aki-gun

Research Site, Hiroshima

Research Site, Sapporo

Research Site, Sanuki

Research Site, Takamatsu

Research Site, Kamakura

Research Site, Kawasaki

Research Site, Yokohama

Research Site, Zushi

Research Site, Kochi

Research Site, Sendai

Research Site, Matsumoto

Research Site, Osaka

Research Site, Suita

Research Site, Ōtsu

Research Site, Atami

Research Site, Shizuoka

Research Site, Komatsushimachō

Research Site, Chiyoda City

Research Site, Chūō

Research Site, Mitaka

Research Site, Ōta-ku

Research Site, Shibuya City

Research Site, Shinjuku

Research Site, Taitō City

Research Site, Takaoka

Research Site, Toyama

Research Site, Ube

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY